ENTRADA THERAPEUTICS, INC. (TRDA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 21.37M USD | Liabilities, Current |
| Cash and equivalents | 99.28M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $21.37M | $99.28M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $19.20M | $76.44M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $24.45M | $90.39M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $24.02M | $93.29M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $19.80M | $72.48M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $18.43M | $67.84M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $39.48M | $101.21M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $70.60M | $78.05M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $85.81M | $185.25M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $173.94M | $68.44M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $158.80M | $67.60M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $165.43M | $51.88M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $125.94M | $79.74M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $147.59M | $227.65M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $21.97M | $45.16M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $21.55M | $53.31M | $162.26M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $18.08M | $90.87M | $153.39M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $15.43M | $84.64M | $179.26M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $6.72M | $291.06M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $7.16M | $122.17M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.36M | $39.05M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |